Breakdown | |||||
TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
1.98B | 2.01B | 1.99B | 1.97B | 1.91B | 1.73B | Gross Profit |
446.44M | 454.34M | 421.56M | 467.03M | 513.24M | 449.32M | EBIT |
153.98M | -68.71M | 7.32M | 172.69M | 202.92M | 173.52M | EBITDA |
-47.54M | -28.37M | 29.89M | 235.64M | 249.88M | 200.37M | Net Income Common Stockholders |
-82.37M | -99.07M | -60.41M | 66.33M | 130.96M | -9.58M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
219.18M | 348.51M | 177.74M | 9.82M | 387.39M | 1.23B | Total Assets |
1.99B | 2.15B | 2.22B | 2.35B | 2.72B | 3.35B | Total Debt |
655.32M | 662.31M | 701.65M | 753.57M | 1.07B | 1.80B | Net Debt |
556.34M | 432.37M | 628.39M | 743.74M | 678.44M | 680.87M | Total Liabilities |
1.20B | 1.39B | 1.37B | 1.46B | 1.83B | 2.60B | Stockholders Equity |
789.19M | 764.94M | 849.06M | 891.63M | 896.69M | 747.72M |
Cash Flow | Free Cash Flow | ||||
203.21M | 184.55M | 104.00M | 137.23M | 44.49M | 175.83M | Operating Cash Flow |
223.22M | 206.57M | 137.32M | 166.94M | 76.74M | 204.62M | Investing Cash Flow |
-26.63M | -35.41M | -48.18M | -56.95M | -53.07M | 815.51M | Financing Cash Flow |
-96.72M | -14.48M | -25.71M | -487.55M | -760.12M | -4.16M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
77 Outperform | $1.60B | 14.91 | 11.19% | 2.37% | 19.16% | 31.92% | |
70 Outperform | $1.17B | 35.43 | 6.72% | 2.34% | 14.30% | 76.89% | |
69 Neutral | $981.68M | 37.16 | 11.28% | ― | 30.04% | 43.47% | |
64 Neutral | $1.19B | ― | -10.01% | ― | -1.13% | -17.77% | |
56 Neutral | $1.60B | ― | -91.17% | ― | 3.88% | -34.30% | |
54 Neutral | $5.34B | 3.27 | -45.10% | 3.30% | 16.80% | 0.02% | |
44 Neutral | $957.91M | 282.18 | 42.49% | ― | 9.05% | ― |
On May 8, 2025, Pediatrix Medical Group held its Annual Shareholders’ Meeting, where all nominees for the Board of Directors were elected to serve until the 2026 meeting. Additionally, shareholders ratified the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for 2025 and approved the executive compensation for the 2024 fiscal year on a non-binding, advisory basis.